Long-Term Follow-Up of Adult Patients with Idiopathic Thrombocytopenic Purpura after Splenectomy

Pavkovic, Marica; Trpkovska-Terzieva, Slobodanka; Latifi, Arif; Каранфилски, Оливер; Čevreska, Lidija; Stojanović, Aleksandar

doi:10.3889/mjms.1857-5773.2011.0188

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median duration of response was reported in five studies, ranging from 29.5 months to 120 months with a median of 81 months. The rate of relapse ranged from 0% to 81.8% with a median rate of 20%, and the median rate of significant bleeding was 4.76% (range 0% to 28.1%). Mortality rates ranged from 0% among multiple studies to 28.8% (over a median follow‐up time of 18 years) (median 2% across studies).…”

Section: Resultsmentioning

confidence: 99%

Systematic literature review of treatments used for adult immune thrombocytopenia in the second‐line setting

et al. 2018

View full text Add to dashboard Cite

Immune thrombocytopenia (ITP) is a rare platelet disorder that is often persistent or chronic in adults. Patient management is dependent upon physician judgment and patient preference, given both the rarity of the condition and a paucity of high‐quality clinical trial evidence to inform practice guidelines. A systematic literature review was conducted to provide an up‐to‐date summary of studies evaluating the safety and efficacy/effectiveness of therapies used to treat adults with primary ITP in the second‐line setting. Using comprehensive search strings, several medical research databases were queried. Final abstraction was performed on 186 articles. Most (75%) studies were observational in nature; nearly half were conducted in Europe. Splenectomy was the most commonly studied (n = 83, 47%), followed by rituximab (n = 49, 26%) and the thrombopoietin‐receptor agonists (TPO‐RAs) romiplostim (n = 34, 18%) and eltrombopag (n = 24, 13%). Twelve prospective, randomized controlled trials (RCTs) with a placebo or standard‐of‐care arm evaluating the safety and efficacy of either rituximab or a TPO‐RA were identified and described in detail. These trials provide important information on the safety and efficacy of these treatments, and in the absence of head‐to‐head data, offer insights on how these therapies compare with one another in treating adult ITP in the second‐line setting. This review confirms that for most second‐line ITP treatment options, there remains a lack of rigorous evidence derived from RCTs, and for many treatments, there is limited evidence of any kind. The need for additional research to guide treatment choices in this setting and greater use of standardized ITP terminology are highlighted.

show abstract